Entities / Company
HUMIRA.
Czech company
- Reports this week
- 2
- Active events
- 1
- Connections
- 22
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
-
AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.Well supported5 reports1 development inside
-
AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.Well supported3 reports4 developments inside
-
AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.Some support4 reports
-
AbbVie overcame the loss of Humira exclusivity, leading to a stock rally while Pfizer stock sank.Some support2 reports
-
Declining sales of Humira due to biosimilar erosion.Well supported7 reports2 developments inside
-
Eight biosimilars for Humira were launched on October 8, 2026, increasing competition in the market.Some support1 report
One to three months ago
Gone quiet
No new reports in 90+ days-
cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.Some support1 report
-
The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.Some support2 reports
-
AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.Speculative2 reports
-
Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.Some support1 report1 development inside
-
MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.Some support2 reports
-
FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.Some support1 report
No events began in the chosen period. Widen it, or reset.
What's reaching HUMIRA
Events traced to HUMIRA, step by step, newest firstAround HUMIRA this week
News at the entities that move HUMIRA most-
Bristol-Myers Squibb StructuralGardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.Moves HUMIRA
-
Medicare OperationalA district judge ruled in Massachusetts v. Oz, and attorneys general from 24 states filed a suit regarding CMS's Medicaid work requirements.Moves HUMIRA
-
Eli Lilly and Company OperationalHouthis actions and Iran's geopolitical moves are elevating gas prices, prompting investors to rotate into safer, low-growth sectors.Moves HUMIRA
-
AbbVie StructuralFed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.Moves HUMIRA
-
Europe Shared contextTrump's interventions are cited as preventing global nuclear conflict as the EU discusses Ukraine reconstruction and security talks in Brussels.Moves HUMIRA
-
Harvard Medical School Mentioned togetherTiziana Life Sciences developed the drug foralumab, and Tanuja Chitnis is a professor at Harvard Medical School.Moves HUMIRA
Connections
The 8 strongest of 22, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie's financial performance and corporate strategy were historically dependent on Humira's market status and patent lifecycle.
-
Bristol-Myers Squibb Structural
The company utilizes the product as a core part of its therapeutic offerings, which are currently facing market pressures from biosimilar competition.
-
Alvotech Operational
Alvotech is developing a biosimilar product intended to compete directly with Humira in the market.
-
Eli Lilly and Company Operational
The relationship is characterized by market competition, where Eli Lilly's growth offsets the decline of Humira.
-
Vanderbilt University School of Medicine Shared context
The entities share a relevant research/market context as biosimilar drugs targeting the same conditions as Humira.
-
Harvard Medical School Mentioned together
HMS researchers are studying the biosimilar competition and generic market dynamics surrounding the drug HUMIRA.
-
Medicare Operational
Medicare operates in a market where generic and biosimilar competition drives down prices, affecting HUMIRA's competitive landscape.
-
Europe Shared context
Humira's patent protection was lost in Europe.
History
Events by the month they beganOctober 2026
2 eventsSeptember 2026
1 eventJune 2026
12 events- AbbVie products are succeeding Humira in the market, while FDA approvals and Fed caution influence market expectations.
- AbbVie's product portfolio was bolstered by the acquisition of Allergan, while Humira sales faced erosion due to patent loss and biosimilar competition.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- AbbVie's Humira is losing exclusivity and facing intense competition from Skyrizi and Rinvoq.
- Declining sales of Humira due to biosimilar erosion.
- Lost patent protection for Humira in the US on August 20, 2025.
- cAMPfield Therapeutics is seeking alternatives to drugs like Humira, while Blackstone invests in drug development deals.
- The patent expiry of Humira is weighing on sentiment, influenced by geopolitical uncertainty in the Middle East.
- AbbVie, which lost exclusivity for Humira, is facing potential tariffs on pharmaceutical imports from the Trump administration.
- Johnson & Johnson tested nipocalimab against Humira, while Amgen is noted for biosimilar competition in the market for Humira.
- MoonLake Immunotherapeutics' sonelokimab demonstrated superior performance compared to Humira in multiple Psoriasis metrics.
- FDA recognized Hadlima as an interchangeable biosimilar for Humira, supporting Organon's biosimilars pipeline.